IntelGenx, through its cutting edge formulation platforms, has developed a broad and diverse product portfolio, including products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products.
IntelGenx Secures Leadership Succession
Dr. Rajiv Khosla has been appointed Chief Operating Officer and Chief Scientific Officer at IntelGenx. He will succeed Dr. Horst Zerbe as CEO and President of the Company on January 1, 2014. Dr. Zerbe will remain as Chairman of the IntelGenx board. The appointment ensures a smooth leadership succession, continuity and fosters growth.
Rajiv Khosla RPh, PhD, MBA
IntelGenx has three proprietary delivery platforms, including an immediate release oral film, VersaFilm™, a mucoadhesive tablet, AdVersa™ and multilayer controlled release tablet, VersaTab™. IntelGenx has an aggressive product development initiative that primarily focuses on addressing unmet market needs. Our rapidly growing product pipeline consists of products at various stages of development from inception to commercialization.
We are proud of our ability to provide and develop a wide and highly diverse range of products catering for present and future commercial needs. Our highly qualified and diversified team provides expertise and services in the following area: formulation development, analytical testing and method development, scale up and technology transfer, manufacturing support, regulatory, clinical research and intellectual properties.